Studies of sulfamethoxydiazine

Publisher Website
Google Scholar
Abstract
Studies are reported comparing the antibacterial activity and chemical levels of sulfamethoxydiazine, a new long‐acting sulfonamide, in serum and plasma of humans. Eleven subjects were treated with various dose schedules for 7 to 10 days; blood samples were taken at the expected daily low and high sulfonamide concentrations. Serum and plasma antibacterial activity was the same. A tendency for each subject to show a positive linear correlation between sulfonamide concentration and antibacterial titer of serum or plasma was noted. This could be demonstrated whether drug levels were compared with antimicrobial activity or whether the sulfonamide concentration was studied at selected titers of antibacterial activity. The 95 per cent confidence limits for the group, however, were very broad and indicated that prediction of either antibacterial activity or sulfonamide concentration from knowledge of the other was not possible. In general, the administration of 1.5 to 2.0 Gm. of sulfamethoxydiazine initially and 0.5 Gm. daily produced blood levels of 7 to 12 mg. per 100 ml. and bacterial inhibition at titers of 1:32 and 1:64. On this basis, this dose of sulfamethoxydiazine is recommended tor therapy.

This publication has 0 references indexed in Scilit: